LibraryBy pinki shah / May 14, 2022 Speciality — Amyotrophic Lateral Sclerosis (ALS) Biomarkers Biosimilars Bladder Blood Bone Brain Breast Cancer Central Nervous System (CNS) Clinical Trials Colon Colorectal Diversity, Equity & Inclusion Featured Content Gastrointestinal Genitourinary Genomic Geriatric Gynecology Head and Neck Hematologic Hematologic Maglinencies Hematology Immunotherapy Interventional Radiology Kidney Leukemia Liquid Biopsy Liver Lung Lymphoma Malignencies Melanoma Myelodysplastic Syndrome Myeloma Neuroendocrine Novel Oral & Maxillofacial Surgery Ovarian Pancreas Pancreatic Pharmacological Prostate Radiation Radiology Renal Sarcoma Skin Solid Tumor Supportive & Palliative Care Survivorship Telemedicine Thoracic Thrombosis Thymic Thyroid Urothelial Author / Speaker Title of Presentation Type of Media — Video Document Audio Event 2024 Event — 2024 California Cancer Consortium Conference (CCC) 2024 MLS Cleveland 2024 MLS Nashville 2024 MLS New Orleans 2024 MLS Seattle 2024 New Orleans Summer Cancer Meeting (NOSCM) 2024 PRIMO 2024 SPS Puerto Rico 2024 SPS Seattle 2024 SPECTRUM 2024 Sylvester APP Oncology Symposium 2024 WCS Clear Displaying 1,651 - 1,675 of 2,711 « 1 … 65 66 67 68 69 … 109 » Stage IIIA-B-C NSCLC: Does The PACIFIC Data Fit All-in-One? By: Jorge E. Gomez, MD View Video Novel Advances in Mesothelioma By: Jorge E. Gomez, MD View PDF Novel Advances in Mesothelioma By: Jorge E. Gomez, MD View Video Stage III NSCLC: Beyond the PACIFIC/ Novel Approaches By: Jorge Gomez, MD View PDF Approach to NSCLC With Targetable Mutations (EGFR, ALK and ROS-1) By: Jorge J Nieva, M.D. View PDF Approach to NSCLC With Targetable Mutations (EGFR, ALK and ROS-1) By: Jorge J Nieva, M.D. View Video Advances in Small Cell Lung Cancer and Mesothelioma By: Jorge J. Nieva, MD View PDF Updates in Immunotherapy for Lung Cancer By: Jorge J. Nieva, MD View PDF Updates in Immunotherapy for Lung Cancer By: Jorge J. Nieva, MD View Video Advances in Small Cell Lung Cancer and Mesothelioma By: Jorge Nieva, MD View Video Updates in Treatment of Early Stage and Locally Advanced NSCLC By: Jorge Nieva, MD View PDF Updates in Treatment of Early Stage and Locally Advanced NSCLC By: Jorge Nieva, MD View Video Updates in Locally Advanced Unresectable (Stage III) NSCLC By: Jorge Nieva, MD View PDF EGFR: Common and Uncommon Mutations - What Is Next for These Patient Populations? By: Joshua Bauml, MD View PDF Masters Debate on Lung Cancer-After Neoadjuvant Therapy for Early-Stage NSCLC, if Surgical Pathology Showed pCR- Would You Offer Adjuvant Therapy? (Part 2) By: Joshua Reuss,MD View PDF Best Approaches for First Line EGFR Mutant NSCLC By: Joshua Sabari, MD View PDF Best Approaches for First Line EGFR Mutant NSCLC By: Joshua Sabari, MD View Video ALK & ROS-1: First Line & Mechanism of Resistance By: Julia Rotow, MD View PDF Mechanism of Resistance to EGFR-ALK & Other Relevant Pathways By: Julia Rotow, MD View Video Mechanism of Resistance to EGFR-ALK & Other Relevant Pathways By: Julia Rotow, MD View PDF ALK & ROS-1: First Line & Mechanism of Resistance By: Julia Rotow, MD View Video ADC in NSCLC: CEACAM5 and Teliso-V By: Julia Rotow, MD View PDF ADC in NSCLC: CEACAM5 and Teliso-V By: Julia Rotow, MD View Video ROS-1 & B-Raf Inhibitors: New Developments By: Julia Rotow, MD View PDF ROS-1 & B-Raf Inhibitors: New Developments By: Julia Rotow, MD View Video
